Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene

• Published in: Blood coagulation & fibrinolysis Vol. 11; no. 5; pp. 485 - 490
• Main Authors: González Ordóñez, A J, Fernández Carreira, J M, Medina Rodríguez, J M, Sánchez, L Martín, Alvarez Díaz, R, Alvarez Martinez, M V, Coto Garcia, E
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Lippincott Williams & Wilkins, Inc 01-07-2000; The Scientist
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Child; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Female; Gene Deletion; Genotype; Humans; Male; Medical sciences; Middle Aged; Mutagenesis, Insertional; Peptidyl-Dipeptidase A - genetics; Protein C Deficiency - genetics; Protein S Deficiency - genetics; Pulmonary Embolism - genetics; Thrombophilia - genetics; Venous Thrombosis - genetics; Human; Enzyme; Insertion; Cardiovascular disease; Genetic determinism; Vascular disease; Peptidases; Gene; Peptidyl-dipeptidase A; Risk factor; Race; Deletion; Hydrolases; Peptidyl-dipeptidases; Caucasoid; Thromboembolism; Vein; Polymorphism
• ISSN: 0957-5235; 1473-5733
• DOI: 10.1097/00001721-200007000-00011

The circulating levels of angiotensin I-converting enzyme (ACE) are linked with a 287-base pair insertion/deletion (I/D) polymorphism at intron 16 of the ACE gene. Thus, the homozygous deletion (D/D genotype) could cause chronic vasoconstriction, arterial hypertension and, possibly, coronary artery disease. Also, the increase in plasminogen activator inhibitor-1 level and impaired fibrinolysis were related with the D/D genotype. The D allele has been recently associated with venous thrombosis among African–American men as well as among patients that underwent elective total hip replacement. We assess the risk of venous thromboembolism (VTE) linked with each genotype of the I/D ACE gene polymorphism in a Caucasian population by means of a case-control study. We genotyped the ACE gene in a series of 148 patients aged 45.0 ± 16.0 years (range, 11–80 years), objectively diagnosed in our centre of deep-vein thrombosis or pulmonary embolism, and in 240 thrombosis-free subjects (25–75 years) from the same geographic area. The observed difference in D allele frequencies between patients (0.56) and controls (0.62) was nonsignificant overall; however, statistical significance (P= 0.05) was found by considering the recessive hypothesis (D/D versus I/D + I/I) [odds ratio (OR) = 0.64, 95% confidence interval (CI95) = 0.42–0.99]. The OR was 0.88 (CI95 = 0.51–1.53;P= 0.65) for the dominant hypothesis (D/D + I/D versus I/I genotypes). The relative risk for the D allele was close to 1 for the dominant hypothesis, both considering gender and recurrent tendency; however, it was protective in men regarding the recessive hypothesis (OR = 0.53, CI95 = 0.29–0.97,P= 0.04). The I/D ACE allele distribution was similar among the 46 thrombophilic patients (antithrombin, protein C or protein S deficiencies, factor V R506Q, factor II G20210A or lupus anticoagulant). In conclusion, among (Spanish) Caucasians, this study does not support the hypothesis that the deletion allele (D) of the ACE gene could be a significant risk factor for VTE, being protective in men.